How to buy Lantheus stock (LNTH)

Lantheus is a drug manufacturers - specialty & generic business based in the US. Lantheus shares (LNTH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $93.25 – an increase of 4.44% over the previous week. Lantheus employs 834 staff and has a trailing 12-month revenue of around $1.5 billion.

Our top picks for where to buy Lantheus stock

Buy Lantheus stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Lantheus stock price (NASDAQ: LNTH)

Use our graph to track the performance of LNTH stocks over time.

Lantheus shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$93.25
52-week range	$50.20 - $126.89
50-day moving average more info button	$95.79
200-day moving average more info button	$89.56
Wall St. target price	$134.69
PE ratio more info button	15.1661
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$6.02

Is it a good time to buy Lantheus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lantheus price performance over time

Historical closes compared with the close of $91.3 from 2024-12-24

1 week (2024-12-20)	2.26%
1 month (2024-11-27)	1.14%
3 months (2024-09-27)	-14.96%
6 months (2024-06-27)	12.29%

1 year (2023-12-27)	48.43%
2 years (2022-12-27)	85.95%
3 years (2021-12-27)	203.32%
5 years (2019-12-27)	350.42%

Is Lantheus stock undervalued or overvalued?

Valuing Lantheus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lantheus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Lantheus's P/E ratio

Lantheus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Lantheus shares trade at around 15x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Lantheus's PEG ratio

Lantheus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Lantheus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Lantheus's EBITDA

Lantheus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $548.1 million.

The EBITDA is a measure of a Lantheus's overall financial performance and is widely used to measure a its profitability.

Lantheus financials

Revenue TTM	$1.5 billion
Operating margin TTM	35.31%
Gross profit TTM	$581.7 million
Return on assets TTM	17%
Return on equity TTM	45.53%
Profit margin	28.57%
Book value	$16.97
Market Capitalization more info button	$6.3 billion

TTM: trailing 12 months

Lantheus share dividends

We're not expecting Lantheus to pay a dividend over the next 12 months.

Lantheus share price volatility

Over the last 12 months, Lantheus's shares have ranged in value from as little as $50.2 up to $126.8899. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantheus's is 0.512. This would suggest that Lantheus's shares are less volatile than average (for this exchange).

Lantheus overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc. ; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC.

Frequently asked questions

What percentage of Lantheus is owned by insiders or institutions?
Currently 2.472% of Lantheus shares are held by insiders and 106.766% by institutions. How many people work for Lantheus?
Latest data suggests 834 work at Lantheus. When does the fiscal year end for Lantheus?
Lantheus's fiscal year ends in December. Where is Lantheus based?
Lantheus's address is: 201 Burlington Road, Bedford, MA, United States, 01730 What is Lantheus's ISIN number?
Lantheus's international securities identification number is: US5165441032 What is Lantheus's CUSIP number?
Lantheus's Committee on Uniform Securities Identification Procedures number is: 516544103